Evaluation of ranirestat for the treatment of diabetic neuropathy

Bibliography

• DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 2010;123(Suppl 3):S38–48
   PubMedGoogle Scholar
• DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 2010;123(Suppl 3):S1–2
   PubMedGoogle Scholar
• Freeman JS. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors. Postgrad Med 2013;125(3):214–26
   PubMed Web of Science ®Google Scholar
• Mehanna A. Antidiabetic agents: past, present and future. Future Med Chem 2013;5(4):411–30
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159(4):262–74
   PubMed Web of Science ®Google Scholar
• Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007;67(7):997–1026
   PubMed Web of Science ®Google Scholar
• Nair M. Diabetes mellitus, part 1: physiology and complications. Br J Nurs 2007;16(3):184–8
   PubMedGoogle Scholar
• Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007;369(9575):1823–31
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33(10):2285–93
   PubMed Web of Science ®Google Scholar
• Toth C, Martinez J, Zochodne DW. RAGE, diabetes, and the nervous system. Curr Mol Med 2007;7(8):766–76
   PubMed Web of Science ®Google Scholar
• Zochodne DW. Diabetic neuropathies: features and mechanisms. Brain Pathol 1999;9(2):369–91
   PubMed Web of Science ®Google Scholar
• Zochodne DW. Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve 2007;36(2):144–66
   PubMed Web of Science ®Google Scholar
• Hamada Y, Nakamura J. Clinical potential of aldose reductase inhibitors in diabetic neuropathy. Treat Endocrinol 2004;3(4):245–55
   PubMedGoogle Scholar
• El-Kabbani O, Ruiz F, Darmanin C, Chung RP. Aldose reductase structures: implications for mechanism and inhibition. Cell Mol Life Sci 2004;61(7-8):750–62
   PubMed Web of Science ®Google Scholar
• Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002;50:325–92
   PubMed Web of Science ®Google Scholar
• Obrosova IG, Kador PF. Aldose reductase/ polyol inhibitors for diabetic retinopathy. Curr Pharm Biotechnol 2011;12(3):373–85
   PubMed Web of Science ®Google Scholar
• Petrash JM. All in the family: aldose reductase and closely related aldo-keto reductases. Cell Mol Life Sci 2004;61(7-8):737–49
   PubMed Web of Science ®Google Scholar
• Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol 2012;3:87
   PubMed Web of Science ®Google Scholar
• Zhu C. Aldose reductase inhibitors as potential therapeutic drugs of diabetic complications. In: Oguntibeju OO, editor. Diabetes mellitus: insights and perspectives. InTech, Rijeka, Croatia; 2013. p. 17–46
   Google Scholar
• Alexiou P, Pegklidou K, Chatzopoulou M, et al. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr Med Chem 2009;16(6):734–52
   PubMed Web of Science ®Google Scholar
• Chung SS, Ho EC, Lam KS, Chung SK. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 2003;14(8 Suppl 3):S233–6
   PubMed Web of Science ®Google Scholar
• Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 2000;77:S3–12
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005;26(3):380–92
   PubMed Web of Science ®Google Scholar
• Gonzalez RG, Barnett P, Cheng HM, Chylack LT Jr. Altered phosphate metabolism in the intact rabbit lens under high glucose conditions and its prevention by an aldose reductase inhibitor. Exp Eye Res 1984;39(5):553–62
   PubMed Web of Science ®Google Scholar
• Allen DA, Yaqoob MM, Harwood SM. Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications. J Nutr Biochem 2005;16(12):705–13
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54(6):1615–25
   PubMed Web of Science ®Google Scholar
• Cohen RA. Role of nitric oxide in diabetic complications. Am J Ther 2005;12(6):499–502
   PubMedGoogle Scholar
• Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant 2005;20(12):2601–4
   PubMed Web of Science ®Google Scholar
• Niedowicz DM, Daleke DL. The role of oxidative stress in diabetic complications. Cell Biochem Biophys 2005;43(2):289–330
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Kukidome D, Sonoda K, et al. Impact of mitochondrial ROS production on diabetic vascular complications. Diabetes Res Clin Pract 2007;77(Suppl 1):S41–5
   PubMedGoogle Scholar
• Williams MD, Nadler JL. Inflammatory mechanisms of diabetic complications. Curr Diab Rep 2007;7(3):242–8
   PubMedGoogle Scholar
• Triplitt CL. New technologies and therapies in the management of diabetes. Am J Manag Care 2007;13(Suppl 2):S47–54
   PubMed Web of Science ®Google Scholar
• Triplitt CL. Managing diabetes in patients with diabetes of long duration. Diabetes Educ 2012;38(4 Suppl):23S–30S; quiz 31S
   PubMedGoogle Scholar
• Giannoukakis N. Drug evaluation: ranirestat–an aldose reductase inhibitor for the potential treatment of diabetic complications. Curr Opin Investig Drugs 2006;7(10):916–23
   PubMed Web of Science ®Google Scholar
• Giannoukakis N. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Expert Opin Investig Drugs 2008;17(4):575–81
   PubMed Web of Science ®Google Scholar
• Hotta N, Sakamoto N, Shigeta Y, et al. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications 1996;10(3):168–72
   PubMed Web of Science ®Google Scholar
• Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001;24(10):1776–82
   PubMed Web of Science ®Google Scholar
• Bril V, Hirose T, Tomioka S, Buchanan R. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009;32(7):1256–60
   PubMed Web of Science ®Google Scholar
• Bril V, Buchanan RA. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004;27(10):2369–75
   PubMed Web of Science ®Google Scholar
• Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006;29(1):68–72
   PubMed Web of Science ®Google Scholar
• Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999;53(3):580–91
   PubMed Web of Science ®Google Scholar
• Negoro T, Murata M, Ueda S, et al. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3’-pyrrolidine-1,2’,3,5’-tetrone (AS-3201) and its congeners. J Med Chem 1998;41(21):4118–29
   PubMed Web of Science ®Google Scholar
• Kurono M, Fujii A, Murata M, et al. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability. Biochem Pharmacol 2006;71(3):338–53
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Ono Y, Kuromiya A, et al. Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats. J Pharmacol Sci 2008;107(3):340–8
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Ono Y, Kurono M, et al. Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats. J Pharmacol Sci 2008;107(3):231–7
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Ono Y, Kurono M, et al. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux. J Pharmacol Sci 2009;109(2):203–10
   PubMed Web of Science ®Google Scholar
• Nakamura J, Lattimer SA, Greene DA. Transphosphatidylation of sugar alcohols and its implications for the pathogenesis of diabetic complications. Diabetologia 1994;37(11):1147–53
   PubMed Web of Science ®Google Scholar
• Kurono M, Fujiwara I, Yoshida K. Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase. Biochemistry 2001;40(28):8216–26
   PubMed Web of Science ®Google Scholar
• Toide K, Terauchi Y, Fujii T, et al. Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes. Biochem Pharmacol 2004;67(7):1269–78
   PubMed Web of Science ®Google Scholar
• Shinohara M, Masuyama T, Shoda T, et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 2000;1(2):89–100
   PubMedGoogle Scholar
• Ota A, Kakehashi A, Toyoda F, et al. Effects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats. J Diabetes Res 2013;2013:175901
   Google Scholar
• Hamada Y, Kitoh R, Raskin P. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Diabetes 1991;40(10):1233–40
   PubMed Web of Science ®Google Scholar
• Ko BC, Ruepp B, Bohren KM, et al. Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene. J Biol Chem 1997;272(26):16431–7
   PubMed Web of Science ®Google Scholar
• Vander Jagt DL, Hunsaker LA, Robinson B, et al. Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms. J Biol Chem 1990;265(19):10912–18
   PubMed Web of Science ®Google Scholar
• Wang K, Bohren KM, Gabbay KH. Characterization of the human aldose reductase gene promoter. J Biol Chem 1993;268(21):16052–8
   PubMed Web of Science ®Google Scholar
• Papanas N, Ziegler D. Polyneuropathy in impaired glucose tolerance: is postprandial hyperglycemia the main culprit? A mini-review. Gerontology 2013;59(3):193–8
   PubMed Web of Science ®Google Scholar
• Shakher J, Stevens MJ. Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes 2011;4:289–305
   PubMedGoogle Scholar
• Lee SS, Han HS, Kim H. A 5-yr follow-up nerve conduction study for the detection of subclinical diabetic neuropathy in children with newly diagnosed insulin-dependent diabetes mellitus. Pediatr Diabetes 2010;11(8):521–8
   PubMed Web of Science ®Google Scholar
• Fujita Y, Fukushima M, Suzuki H, et al. Short-term intensive glycemic control improves vibratory sensation in type 2 diabetes. Diabetes Res Clin Pract 2008;80(1):e16–19
   PubMedGoogle Scholar
• Booya F, Bandarian F, Larijani B, et al. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurol 2005;5:24
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE. Relation of glycemic control to diabetic complications and health outcomes. Diabetes Care 1998;21(Suppl 3):C39–43
   PubMedGoogle Scholar
• Tkac I, Bril V. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy. Diabetes Care 1998;21(10):1749–52
   PubMed Web of Science ®Google Scholar
• Lloyd CE, Becker D, Ellis D, Orchard TJ. Incidence of complications in insulin-dependent diabetes mellitus: a survival analysis. Am J Epidemiol 1996;143(5):431–41
   PubMed Web of Science ®Google Scholar
• Suljic E, Kulasin I, Alibegovic V. Assessment of diabetic polyneuropathy in inpatient care: fasting blood glucose, HbA1c, electroneuromyography and diabetes risk factors. Acta Inform Med 2013;21(2):123–6
   Google Scholar